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Introduction
Thyroid nodules are frequently detected although their 
prevalence depends on the studied population and the 
methods used to detect them. It is estimated that 2–6% of 
thyroid nodules are detected by palpation whereas 19–35% 
are detected by ultrasound assessment. However, autopsy 
data indicate that the prevalence of thyroid lesions can 
reach even 85% (1-3). The frequency of nodule detection 
increases with age, particularly after 60 years of age. Of 
note, only about 5% of nodular lesions in the thyroid 
are malignant (4,5). Papillary thyroid cancer (PTC) is 
the most frequently detected malignancy (14.3/100,000 
annually in the US) (6). In the recent 4 decades there has 
been a steady increase in the prevalence of PTC (5,7,8). 
Routine assessment of suspicious thyroid lesions is based 
on ultrasound and cytological examination using a fine-
needle aspiration biopsy (FNAB). The most prestigious 
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thyroid associations such as the American Association of 
Clinical Endocrinologists (AACE), the American Thyroid 
Association (ATA) and the European Thyroid Association 
(ETA) provide detailed guidelines on which nodules 
should be biopsied (9-11). The result of the cytological 
examination of the cells collected by FNAB is considered to 
be the most reliable in planning further clinical assessment. 
When malignancy is suspected, surgery is recommended, 
whereas in the case of benign lesions, watchful waiting 
strategy should be adopted.
In 2009, the National Cancer Institute in Bethesda, MD, 
USA proposed a classification of cells in thyroid cytology 
and in 2017 the criteria were revised (12). Currently, it 
is the basic system for reporting thyroid cytopathology 
that is the basis for further clinical management (Table 1). 
The system is known as “Bethesda” and is based on six 
categories, i.e., (I) nondiagnostic/inadequate, (II) benign, 
(III) atypia of undetermined significance/follicular lesion 
of undetermined significance (AUS/FLUS), (IV) follicular 
neoplasm or suspicious for a follicular neoplasm, (V) 
suspicious for malignancy, and (VI) malignant (12).
Although FNAB is a standard and well-recognized 
diagnostic procedure for suspicious thyroid nodules, it has 
certain limitations. The procedure is not easy and requires 
experience. Additionally, the assessment of individual 
cells can be difficult to interpret and poses a challenge to 
pathologists. It is estimated that approximately 20–30% of 
all thyroid nodule biopsies are classified as “indeterminate” 
and are then mainly assessed as Bethesda class III (13), in 
which the risk of thyroid cancer is 6–30% (12) and even 
48% (14) and Bethesda class IV, which mainly refers to the 
suspicion of follicular neoplasm. Among thyroid tumors 
cytologically assessed as “indeterminate” that are surgically 
resected approximately 15–30% are malignant lesions that 
require surgical intervention. As a result, the majority of 
resected nodules are benign and do not require such a 
radical approach. This has a multidimensional meaning 
due to the fact that unnecessary surgery is related to 
constant hormonal treatment and an endocrine follow-up 
of patients throughout life. Postoperative complications 
may also occur, which is associated with the psychological 
burden of patients and a decreased quality of life. Another 
important issue is connected with the economic aspect 
of surgery and postoperative care. This means that 
additional diagnostic markers are needed for the above two 
groups of the Bethesda system classification. As a result, 
other independent factors could add to the cytological 
picture. Sensitivity to detect these lesions is also of crucial 
importance. Such lesions require surgical treatment due to 
high potential of malignancy and aggressiveness.
In the current stage of development of genetic 
techniques, molecular markers seem to be readily available 
and perfectly adopted for routine use in everyday clinical 
practice. Significant progress in understanding the 
molecular biology of thyroid cancer and particularly PTC 
has encouraged many scientists to develop molecular 
classifiers that allow them to differentiate between 
malignant and benign lesions. The results of the Cancer 
Genome Atlas Network systematized knowledge of 
molecular events in PTC (15) and showed that most 
malignant lesions are characterized by changes in the DNA. 
Currently, patients with cytologically indeterminate thyroid 
nodules (Bethesda system) usually undergo diagnostic 
surgery (mainly lobectomy). Therefore, the possible benefit 
of using a molecular classifier in cytological diagnoses of 
indeterminate nodules was considered in the 2nd edition 
Table 1 TBSRTC and usual management after diagnosis
Category of the 
Bethesda system 
Meaning Usual management
I Non-diagnostic or inadequate Repeat FNA with ultrasound guidance
II Benign Clinical follow-up
III AUS/FLUS Repeat FNA, molecular testing, lobectomy  
(diagnostic surgery)
IV Follicular neoplasm or suspicious for a follicular neoplasm Molecular testing, lobectomy (diagnostic surgery) 
V Suspicious for malignancy Lobectomy or near-total thyroidectomy
VI Malignant Lobectomy or near-total thyroidectomy
TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology; FNA, fine-needle aspiration; AUS/FLUS, atypia of undetermined sig-
nificance/follicular lesion of undetermined significance.
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of The Bethesda System for Reporting Thyroid Cytopathology 
(TBSRTC) and in the ATA guidelines (9,12). According 
to these recommendations, the use of molecular tests is 
useful to assess the risk of malignancy so that unnecessary 
diagnostic surgery could be avoided.
Additionally, the introduction of a new diagnosis by 
the WHO in 2017 is an important aspect in the diagnosis 
of thyroid cancer. Classification of Tumors of Endocrine 
Organs reclassified thyroid tumors and classified tumors 
of endocrine organs by introducing a new section termed 
“other encapsulated follicular-patterned thyroid tumors” (16). 
This section includes diagnoses termed uncertain malignant 
potentials, which include follicular tumor of uncertain 
malignant potential, well-differentiated tumor of uncertain 
malignant potential and a new diagnosis, i.e., non-invasive 
follicular thyroid neoplasm with papillary-like nuclear 
features (NIFTP) that is considered a benign lesion more 
similar to follicular adenoma in the clinical course of the 
disease (17).
NIFTP arouses great interest in relation to preoperative 
diagnosis. To exclude the malignancy of this tumor, it is 
necessary to rule out any features of invasion that cannot 
be assessed in biopsy material. Therefore, despite the 
fact that the use of FNAB of thyroid nodules has reduced 
unnecessary surgical treatment, it is still not a sufficient 
method and requires other supportive methods.
Preoperative diagnosis of thyroid cancer—from 
a single gene to a molecular classifier
The use of immunohistochemical (IHC) markers that assess 
the malignancy of lesions was the first stage of searching for 
markers that would increase the sensitivity of FNAB. The 
use of the following markers was postulated: galectin-3, 
HBME, fibronectin 1 or cytokeratin 19. However, they 
proved to be insufficient for the assessment of biopsy 
material (18-21). It was mainly due to the fact that the use 
of different antibodies and different visualization methods 
results in difficulties in the interpretation of the IHC. 
Additionally, the expression of these markers may be also 
detected in follicular adenomas (22,23).
The increasing knowledge on molecular changes at the 
DNA level in thyroid cancer cells is a promising field in the 
search for molecular markers. Of note, knowledge related 
to the molecular basis of thyroid cancer was mainly related 
to postoperative material. Only in the last decade has there 
been an increase in studies using biopsy material. These 
studies are connected with the analysis of changes in the 
DNA sequence (DNA mutations) and gene expressions 
(mRNA analysis).
Due to the fact that PTC is the most prevalent thyroid 
cancer, it is also best known in terms of molecular 
characteristics. The first attempts to use the selection of 
malignant lesions based on cytology were made using single 
molecular markers most commonly observed in PTC such 
as BRAF gene mutations, RET and NTRK rearrangements 
(24-30) or PAX8/PPARγ fusion characteristic of follicular 
tumors. However, these alterations do not always occur 
in malignant tumors and the absence of BRAF mutation 
does not mean that the lesion has no malignant potential. 
BRAF mutation can be an important marker determining 
tumor malignancy but mainly in the countries where 
the prevalence of this mutation is high and reaches even 
83% (25). However, the prevalence of BRAF mutation in 
European countries ranges from 50% to 70% (31,32). In 
addition, due to the potential tumor heterogeneity, it can 
occur in single cell clones and may not be detected when 
low-sensitivity methods are used.
For this reason, multi-gene panels were tested. As 
a result, the first tumor-specific mutations test was 
developed from seven genes most characteristic of PTC 
and follicular thyroid cancer, i.e., point mutations within 
BRAF, KRAS, HRAS and NRAS genes, and RET/PTC1, 
RET/PTC3 and PAX8/PPARγ rearrangements (33). After 
discovering an important role of the NTRK genes family 
fusion, these molecular markers were also included in the 
classifier (34). The analytical sensitivity of the molecular 
test ranged from 38% to 85.6% and the specificity ranged 
from 95% to 100%. RAS genes mutations and PPRG/
PAX8 rearrangement show the lowest sensitivity since 
they occur in benign and malignant lesions with a variable 
frequency. Of note, the first tests were performed using 
molecular techniques of limited sensitivity. However, it was 
the introduction of highly sensitive and highly effective 
methods such as oligonucleotide microarrays and next 
generation sequencing (NGS) that allowed the detection 
of mutations or gene expressions that were present even in 
small amounts.
The first gene panel for preoperative diagnostic use, 
defined as a molecular classifier, was presented in 2010 (35). 
The classifier was based on the assessment of the expression 
of 147 genes selected in the study using high density 
oligonucleotide microarrays. This study was extended 
by a multicenter prospective study, which involved over 
3,900 patients (36).
It was the turning point for preoperative molecular 
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diagnosis of thyroid tumors. The first NGS test based 
on the assessment of changes in the DNA sequence for 
15 genes was presented in 2013 (37). NGS method allows 
the assessment of many gene alterations in one analysis. 
Next, miRNA-based classifier was developed (38). In fact, 
all the above classifiers form two groups of tests although all 
of them have the same aim, which is to distinguish between 
malignant and benign lesions in biopsy material. Some of 
these classifiers are used to exclude malignant lesions (“rule-
out” test), while the others are used to confirm malignant 
lesions (“rule-in” test). Both types of tests are determined 
by two values, i.e., negative predictive value (NPV) and 
positive predictive value (PPV). However, the NPV value 
allows to assess the probability of benign lesions when 
the result is negative (the higher the NPV, the higher the 
probability of a benign lesion). PPV, on the other hand, 
allows to assess the probability of malignant lesions when 
the result is positive (the higher the PPV, the higher the 
probability of a malignant lesion) in a given population. 
The use of the “rule-in” and “rule-out” molecular tests is 
given in Figure 1.
Commercially available molecular tests used in 
preoperative diagnosis of thyroid cancer—are 
they useful to endocrinologists and surgeons in 
Europe?
Until recently, there were 4 companies on the US market 
that offered commercial tests for preoperative diagnosis of 
thyroid nodules (Veracyte Inc., CBLPath Inc., Interpace 
Diagnostics Inc. and Rosetta Genomics Inc.). The test 
developed by Rosetta Genomics Inc., after its bankruptcy, 
was taken over by Interpace Diagnostics Inc. (Table 2).
The first commercial molecular test for preoperative 
diagnosis of thyroid nodules was the Afirma gene expression 
classifier (GEC) test or its new version known as genomic 
sequencing classifier (GSC; Veracyte Inc., South San 
Francisco, CA, USA). This is a “rule-out” test which 
provides the information whether the lesion is benign or 
suspicious. The first version of this test (GEC) is based on 
the assessment of mRNA expression using high density 
oligonucleotide microarrays and was developed on the basis 
of a 2010 study by Chudova et al. (35). The test is divided 
into several steps.
The first step includes the assessment of the expression 
of 25 genes typical of metastases of other cancers to 
the thyroid gland (breast cancer, kidney carcinoma and 
melanoma) and Hürthle cell and medullary thyroid cancer 
(MTC). If the result is defined as “suspicious” or “MTC”, 
the analysis is terminated and suggests metastasis to 
the thyroid or MTC. On the other hand, if the result is 
negative, the appropriate stage of the analysis is introduced, 
i.e., the assessment of the expression of 142 genes. At this 
stage, the result is either “benign” or “suspicious”. When 
the lesion is suspicious, additional assessment of BRAF gene 
mutation and RET/PTC1 and RET/PTC3 rearrangements is 
performed. Of note, the aim of the test is to confirm benign 
lesions (NPV of 94%, sensitivity of 90%; PPV is low and is 
of 37%). The test has also some disadvantages as malignant 
lesions derived from Hürthle cells cannot be assessed 
using this test. In 2018, the latest version of the GSC was 
introduced (39). It is based on the NGS technique. Both 
Figure 1 The use of the molecular tests in preoperative diagnosis of thyroid tumors. NPV, negative predictive value; PPV, positive predictive 
value.
Fine needle biopsy of thyroid nodules
Bethesda II Bethesda V, VI
Appropriate management Appropriate management
Bethesda III, IV
"indeterminate cytology"
High NPV High PPV
Molecular test
Benign Malignant
Rule-out test Rule-in test
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gene expression and mutations are assessed. The test was 
developed to analyze several thousand genes to better detect 
lesions derived from Hürthle cells. The estimated cost was 
$6,400 in 2018 (40). It should be borne in mind that the 
Afirma test is most often validated by independent studies. 
Therefore, it is considered the most reliable, commercially 
available test (40-42). Many studies showed that the 
number of cases that required lobectomy was reduced by 
approximately 50% in the AUS/FLUS diagnoses.
ThyroSeq 2 (CBLPath Inc., Rye Brook, New York, 
University of Pittsburgh Medical Center, Pittsburgh, PA, 
USA) is the second most frequent test used in the cytological 
assessment. This test assesses point mutations, small 
insertions and deletions for 14 genes, and evaluates 42 fusion 
genes. The mutations used in the test are related to the 
biology of PTC in as much as 90% (43). The test is intended 
to detect malignant lesions (“rule-in”) and the obtained result 
may be positive or negative. The positive result indicates that 
the lesion has a malignant potential. Interestingly, this test 
has high PPV (83%) and also NPV (96%) (sensitivity 90%; 
specificity 93%). However, it was not so widely validated by 
other independent studies and those which used it showed 
significantly lower PPV and NPV values (44,45). The current 
version of ThyroSeq3 is characterized by sensitivity of 94% 
and specificity of 82% and NPV of 97%, PPV of 66% for 
the cancer prevalence of 28% (46) (Steward, 2018). The cost 
of the test is USD 4,056 (41).
The ThyGenX/ThyraMIR test (Interpace Diagnostics 
Inc., Parsippany, NJ, USA) has the similar characteristics. 
It is based on the assessment of the mutations of 5 genes, 
i.e., BRAF, KRAS, HRAS, NRAS, PIK3CA and 3 gene 
rearrangements, i.e., RET/PTC1, RET/PTC3 and PAX8/
PPARG. It is also a “rule-in” test and is characterized 
by high NPV (94%) and PPV (74%) (sensitivity 89%; 
specificity 85%, respectively) (38). As in the case of the 
ThyroSeq test, the result is either positive or negative. 
However, to obtain high sensitivity and specificity, it should 
be used in combination with second part of the test based on 
the assessment of miRNA expression (ThyraMIR). Of note, 
each step can be performed separately. However, sensitivity 
and specificity are then decreased. The final result of the 
two-step assessment shows high or low probability of 
malignancy. There are no independent validation tests for 
both assays. The cost of the test is USD 5,675 (41).
RosettaGX Reveal (Rosetta Genomics Inc., Philadelphia, 
Pennsylvania, USA, currently Interpace Diagnostics 
Group, Parsippany, NJ, USA) is another test based on 
miRNA expression. It is the only test which also includes 
the European cohort. However, it is not well known and 
has not undergone multicentre validation. It was found 
to have sensitivity of 85%, specificity of 72%, NPV of 
91%, and PPV of 59% (47). Of note, 3 pathologists were 
involved in the cytological assessment, including 1 referring 
pathologist. The estimated cost of the test was USD 3,700 
in 2018 (40).
Recently, it has been announced that simple and low-
cost classifiers have been developed. Those molecular 
tests are based on real-time polymerase chain reaction 
(PCR) method which supports FNAB. The tests assess 
mRNA or microRNA expression. However, they are still 
under research and cannot be commercially used (48,49). 
Interestingly, both tests are based on South American 
population (Chile and Brazil).
All commercial tests are widely available in the United 
States. However, the most significant scientific associations 
are not completely ready to include them in their 
recommendations. The ATA clinical practice guidelines 
recommend a molecular test for diagnosis of indeterminate 
Table 2 Commercially available tests
Molecular test Methodology Type of test Report Source
Afirma GEC/GSC Gene expression analysis (mRNA) Rule-out Benign/suspicious Alexander EK, 2012
Patel KN, 2018
ThyroSeq2/3 Gene mutation analysis (DNA) Rule-in/rule-out Negative/positive Nikiforov YE, 2015
Steward DL, 2018
Rosetta Reveal Gene mutation analysis (DNA) Rule-in Type of detected mutation Lithwick-Yanai G, 2016 
ThyGenX/ThyramiR Gene mutation analysis (DNA) and 
miRNA expression analysis (miRNA)
Rule-in/rule-out when 
both steps are performed
Negative/positive Labourier E, 2015
GEC, gene expression classifier; GSC, genomic sequencing classifier.
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cytology (AUS/FLUS) after consultation with a patient 
who should be informed about the benefit-risk ratio (9). 
However, the AACE guidelines which also focus on the use 
of molecular tests in cytologically indeterminate thyroid 
nodules are limited to recommendations on performing the 
assessment of BRAF and RAS genes mutations and RET/
PTC and PAX8/PPRG rearrangements (10). However, in 
the case of multigene classifiers, these associations neither 
recommend nor prohibit them, which is related to the lack 
of data on a long follow-up period. On the other hand, 
a 2015 survey by ATA revealed that more than 50% of 
American clinicians used a molecular test in their daily 
clinical practice (50). Clinicians (endocrinologists and 
surgeons) choose the test themselves due to the fact that 
there are no clear recommendations on the use of molecular 
tests that support the cytological diagnosis. In the United 
States or high-income European countries, the costs of the 
tests are covered by insurance companies. However, the 
situation is different if the test is to be used in low-income 
countries where costs related to diagnostic procedures and 
treatment are largely covered by public health protection 
systems. Therefore, the most important disadvantage of 
commercially available tests is probably related to their 
price that reaches several thousand dollars. Of note, in 
many European countries this amount of money is equal 
to the cost of thyroidectomy. Additionally, there are also 
other limitations such as the lack of large-scale validation 
tests involving the European population or a too short 
follow-up. These limitations are stressed by European 
experts and therefore they are not included in European 
recommendations on the diagnosis of thyroid nodules (11).
No analyses of currently available molecular classifiers 
(commercial or scientific) have been conducted in Europe 
yet. Of note, there is no molecular test whose price would be 
affordable for all European patients or European health care 
systems. Admittedly, the first results of using a cost-effective 
(EUR 150/sample) molecular classifier in the European 
population was presented during the ETA Conference in 
2019. However, only 109 FNABs were tested (51). The test 
is based on a custom Mass Array platform (PTC-MA), which 
allows the simultaneous detection of 13 hotspot mutations 
and 7 fusion genes characteristic of thyroid cancer (52).
Conclusions
Cytologically indeterminate thyroid nodules pose a 
great challenge to pathologists, clinicians and molecular 
biologists. The use of single molecular markers for thyroid 
cancer might help to detect malignancy in FNAB (e.g., 
BRAF gene mutation). However, this solution is still not 
sufficient. The use of commercially available molecular 
tests significantly reduces the number of patients in whom 
diagnostic surgical intervention is necessary. However, 
validation and prospective studies are still necessary to assess 
the tests in other than the North American population. 
Additionally, the high cost of tests limits their availability in 
low-income countries.
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